Washington Trust Advisors’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Washington Trust Advisors’s Portfolio PEAR Stock Details PEAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,000	Closed	-$765	–	790
2023 Q1	$765	Hold	3,000	–	–	﹤0.01%	765
2022 Q4	$3.54K	Hold	3,000	–	–	﹤0.01%	655
2022 Q3	$6K	Hold	3,000	–	–	﹤0.01%	701
2022 Q2	$5K	Hold	3,000	–	–	﹤0.01%	769
2022 Q1	$15K	Hold	3,000	–	–	﹤0.01%	653
2021 Q4	$19K	Buy	+3,000	New	+$26.8K	﹤0.01%	641

Washington Trust Advisors's PEAR Position: Q2 2023 in Review

Washington Trust Advisors sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2023, closing a stake of 3,000 shares — an estimated $765 sold.

Washington Trust Advisors first reported a position in PEAR in Q4 2021 and held it in 6 quarters. The position peaked at $19K in Q4 2021. 1 fund tracked by Wall St. Rank holds PEAR as of Q2 2023.

Washington Trust Advisors reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Washington Trust Advisors sold 3,000 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2023, an estimated $765.
Washington Trust Advisors first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q4 2021 and held it in 6 quarters.
Washington Trust Advisors's Pear Therapeutics, Inc. Class A Common Stock position peaked at $19K in Q4 2021.
1 fund tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2023.

Based on Washington Trust Advisors's 13F filing for Q2 2023, filed 27 Jul 2023.